The use of trastuzumab and other monoclonal antibodies directed at HER2, such as pertuzumab, has resulted in markedly improved prognosis for women with HER2-positive breast cancers, both by prolonging survival in advanced, metastatic disease and by reducing the risk for cancer recurrence in the adjuvant setting. Here, ERBB2 is linked to breast carcinoma.